Efficacy and Safety of EXOSOME-MSC Therapy to Reduce Hyper-inflammation In Moderate COVID-19 Patients

NCT05216562 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV2 Infection

Interventions

DRUG: Exosome-MSC Intravenous injection
DRUG: Placebo Intravenous Injection
DRUG: COVID-19 Standard Treatment

Sponsor

Dermama Bioteknologi Laboratorium

Collaborators

[object Object]